2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
54
Lymphoma, Mantle-Cell
31
Lymphoma, Large B-Cell, Diffuse
17
Lymphoma, Non-Hodgkin
14
Lymphoma
11
Leukemia, B-Cell
7
Lymphoma, Follicular
5
Lymphoma, B-Cell, Marginal Zone
5
Lymphoma, B-Cell
5
Leukemia
5
Waldenstrom Macroglobulinemia
4
Multiple Myeloma
3
Recurrence
2
Pancreatic Neoplasms
2
Lymphoproliferative Disorders
2
Lymphatic Diseases
2
Leukemia, Prolymphocytic
2
Hematologic Neoplasms
2
Cardiovascular Diseases
2
Squamous Cell Carcinoma of Head and Neck
1
Pyloric Stenosis, Hypertrophic
1
Part1: Advanced B-cell Malignancies
1
Ovarian Neoplasms
1
Neuritis
1
Neoplasms
1
Neoplasm, Residual
1
Leukemia, Hairy Cell
1
Immunoproliferative Disorders
1
Immune System Diseases
1
Hodgkin Disease
1
Interventions
Cyclophosphamide
217
Rituximab
110
Etoposide
99
Peripheral Blood Stem Cell Transplantation
94
Vincristine
91
Filgrastim
91
Cytarabine
91
Methotrexate
90
fludarabine phosphate
85
Radiotherapy
67
Doxorubicin
67
Prednisone
66
Dexamethasone
57
Mycophenolic Acid
53
Cyclosporine
53
Whole-Body Irradiation
50
Busulfan
47
Melphalan
44
blinatumomab
43
Tacrolimus
42
fludarabine
41
Antilymphocyte Serum
40
Methylprednisolone
39
merphos
35
Calcium Dobesilate
34
Leucovorin
33
Granulocyte Colony-Stimulating Factor
30
Mercaptopurine
26
dexamethasone acetate
25
dexamethasone 21-phosphate
25
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Burkitt Lymphoma
×
acalabrutinib
×
Clear all
NCT02362035
2026-05-13
KEYNOTE145
Acerta Pharma BV
Phase 1/2
Completed
161 enrolled
29 charts